<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">678396</article-id><article-id pub-id-type="doi">10.26442/00403660.2026.01.203558</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prevalence and predictors of suboptimal peak inspiratory flow values with metered-dose dry powder inhalers in patients with asthma and chronic obstructive pulmonary disease</article-title><trans-title-group xml:lang="ru"><trans-title>Распространенность и предикторы субоптимальных значений пикового инспираторного потока при использовании дозированных порошковых ингаляторов у пациентов с бронхиальной астмой и хронической обструктивной болезнью легких</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1254-6863</contrib-id><name-alternatives><name xml:lang="en"><surname>Lavginova</surname><given-names>Baina B.</given-names></name><name xml:lang="ru"><surname>Лавгинова</surname><given-names>Баина Баатровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант каф. пульмонологии Института клинической медицины им. Н.В. Склифосовского</p></bio><email>trushenko.natalia@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0685-4133</contrib-id><name-alternatives><name xml:lang="en"><surname>Trushenko</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Трушенко</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. пульмонологии Института клинической медицины им. Н.В. Склифосовского; науч. сотр. Научно-методического центра мониторинга и контроля болезней органов дыхания</p></bio><email>trushenko.natalia@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9509-0867</contrib-id><name-alternatives><name xml:lang="en"><surname>Nekludova</surname><given-names>Galina V.</given-names></name><name xml:lang="ru"><surname>Неклюдова</surname><given-names>Галина Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, доц. каф. пульмонологии Института клинической медицины им. Н.В. Склифосовского; вед. науч. сотр. лаб. функциональных и ультразвуковых методов исследования</p></bio><email>trushenko.natalia@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-1847-4159</contrib-id><name-alternatives><name xml:lang="en"><surname>Belkina</surname><given-names>Olesia S.</given-names></name><name xml:lang="ru"><surname>Белкина</surname><given-names>Олеся Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>студентка Клинического института детского здоровья им. Н.Ф. Филатова</p></bio><email>trushenko.natalia@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5999-2150</contrib-id><name-alternatives><name xml:lang="en"><surname>Avdeev</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Авдеев</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, проф., зав. каф. пульмонологии Института клинической медицины им. Н.В. Склифосовского; вед. науч. сотр.</p></bio><email>trushenko.natalia@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Institute of Pulmonology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2026</year></pub-date><volume>98</volume><issue>1</issue><issue-title xml:lang="en">Outpatient care issues and organization of medical care</issue-title><issue-title xml:lang="ru">Поликлинические проблемы и организация медицинской помощи</issue-title><fpage>35</fpage><lpage>42</lpage><history><date date-type="received" iso-8601-date="2025-04-11"><day>11</day><month>04</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-10-31"><day>31</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/678396">https://ter-arkhiv.ru/0040-3660/article/view/678396</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>A key requirement for effective dry powder inhaler (DPI) use is adequate patient inspiratory effort, measurable through peak inspiratory flow (PIF).</p> <p><bold>Aim. </bold>To assess the prevalence of suboptimal PIF values, and identify factors significantly affecting PIF in pulmonary disease (COPD) and asthma outpatients.</p> <p><bold>Materials and methods. </bold>The study enrolled asthma and COPD patients using DPIs for maintenance therapy. PIF was measured using In-Check DIAL G16<sup>®</sup> at resistance levels matching each patient's DPI, both before and after proper inhalation technique training. Clinical and functional parameters were evaluated to identify predictors of suboptimal PIF.</p> <p><bold>Results. </bold>The study included 61 asthma and 30 COPD patients. Baseline suboptimal PIF rates were 34% (asthma) and 63% (COPD). After training, these decreased significantly to 10% (asthma) and 23% (COPD); <italic>p</italic> &lt; 0.0001. Key limiting factors for achieving optimal PIF were age ≥ 60 years, FVC ≤ 70% predicted, and FEV1 ≤ 45% predicted.</p> <p><bold>Conclusion. </bold>Many patients had insufficient inspiratory flow for effective DPI use due to technique errors or age/functional limitations. Pre-prescription PIF measurement objectively evaluates DPI suitability and enhances treatment efficacy.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Одним из ключевых условий эффективного использования дозированных порошковых ингаляторов (ДПИ) является достаточное инспираторное усилие пациента, которое можно оценить по уровню пикового инспираторного потока (ПИП).</p> <p><bold>Цель. </bold>Изучить распространенность и предикторы развития субоптимальных для ДПИ значений ПИП у пациентов с хронической обструктивной болезнью легких (ХОБЛ) и бронхиальной астмой (БА) в амбулаторной практике.</p> <p><bold>Материалы и методы. </bold>В исследование включались больные БА и ХОБЛ, использующие в качестве базисной терапии ДПИ. Значение ПИП оценивалось с помощью портативного инспираторного флоуметра In-Check DIAL G16<sup>®</sup> на уровне сопротивления соответствующего ДПИ, используемого пациентом, исходно и после объяснения правильной техники ингаляций при БА и ХОБЛ. С целью определения предикторов субоптимального ПИП оценивали основные клинические показатели и параметры комплексного исследования функции дыхания.</p> <p><bold>Результаты. </bold>В исследование вошли 61 пациент с БА и 30 пациентов с ХОБЛ. Доля пациентов с субоптимальными показателями ПИП исходно составляла 34% в группе БА и 63% – в группе ХОБЛ. После обучения правильной технике ингаляции доля пациентов с субоптимальным ПИП значительно снизилась в обеих группах: до 10% в группе БА и до 23% – в группе ХОБЛ (<italic>p</italic> &lt; 0,0001). Наиболее значимыми факторами, существенно ограничивающими вероятность достижения у пациента оптимального ПИП, необходимого для эффективного использования ДПИ, стали возраст ≥ 60 лет, форсированная жизненная емкость легких ≤ 70%долж. и объем форсированного выдоха за 1-ю секунду ≤ 45%долж.</p> <p><bold>Заключение. </bold>Многие пациенты имели недостаточную силу вдоха для эффективного применения ДПИ из-за ошибок в технике ингаляций или возрастных/функциональных ограничений. Измерение ПИП перед назначением ДПИ позволяет объективно оценить возможность его использования и повысить эффективность терапии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>peak inspiratory flow</kwd><kwd>inhalation technique</kwd><kwd>dry powder inhalers</kwd><kwd>bronchial asthma</kwd><kwd>chronic obstructive pulmonary disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пиковый инспираторный поток</kwd><kwd>техника ингаляций</kwd><kwd>дозированные порошковые ингаляторы</kwd><kwd>бронхиальная астма</kwd><kwd>хроническая обструктивная болезнь легких</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Rodriguez-Garcia C, Barreiro E, Muñoz-Gall X, et al. Common errors in inhalation therapy: Impact and solutions. Clin Respir J. 2020;14(11):1001-10. DOI:10.1111/crj.13236</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lannefors L. Inhalation therapy: practical considerations for nebulisation therapy. Physic TherRev. 2006;11:21-7. DOI:10.1179/108331906X98976</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. Chronic Obstr Pulm Dis. 2019;6(3):267-80. DOI:10.15326/jcopdf.6.3.2018.0168.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Çakmaklı S, Özdemir A, Fırat H, Aypak C. An evaluation of the use of inhalers in asthma and chronic obstructive pulmonary disease. J Taibah Univ Med Sci. 2023;18(4):860-7. DOI:10.1016/j.jtumed.2023.01.001</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209-27.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mohan AR, Wang Q, Dhapare S, et al. Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development. Pharmaceutics. 2022;14(11):2495. DOI:10.3390/pharmaceutics14112495</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Mahler DA, Demirel S, Hollander R, et al. High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study. Chronic Obstr Pulm Dis. 2022;9(3):427-38. DOI:10.15326/jcopdf.2022.0291</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Laube BL, Janssens HM, de Jongh FH, et al.; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308-31. DOI:10.1183/09031936.00166410</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers – implications for in vitro testing. J Aerosol Med. 1993;6(2):99-110. DOI:10.1089/jam.1993.6.99</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ganderton D. General factors influencing drug delivery to the lung. Respir Med. 1997;91(Suppl. A):13-6. DOI:10.1016/s0954-6111(97)90099-8</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sanders MJ. Guiding Inspiratory Flow: Development of the In-Check DIAL G16, a Tool for Improving Inhaler Technique. Pulm Med. 2017;1495867. DOI:10.1155/2017/1495867</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Трушенко Н.В., Лавгинова Б.Б., Обухова Н.Е., и др. Роль пикового инспираторного потока в подборе ингаляционной терапии у пациентов с хронической обструктивной болезнью легких. Медицинский Совет. 2023;(20):84-90 [Trushenko NV, Lavginova BB, Obukhova NE, et al. The role of peak inspiratory flow in the selection of inhalation therapy in patients with chronic obstructive pulmonary disease. Meditsinskiy Sovet. 2023;17(20):84-90 (in Russian)]. DOI:10.21518/ms2023-388</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ohar JA, Mahler DA, Davis GN, et al. Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow. Can Respir J. 2024;2024:8034923. DOI:10.1155/2024/8034923</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Silva CPD, Cordeiro JSA, Britto MCA, et al. Peak inspiratory flow in children and adolescents with asthma using dry powder inhalers: a cross-sectional study. J Bras Pneumol. 2021;47(3):e20200473. DOI:10.36416/1806-3756/e20200473</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Plaza V, Fernández-Rodríguez C, Melero C, et al. Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for asthma and COPD patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):142-52. DOI:10.1089/jamp.2015.1212</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. DOI:10.1183/13993003.01499-2021</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Meng W, Xiong R, Zhao Z, et al. Suboptimal peak inspiratory flow rate: a noticeable risk factor for inhaler concordance in patients with chronic airway diseases. BMJ Open Respir Res. 2024;11(1):e001981. DOI:10.1136/bmjresp-2023-001981</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Pankovitch S, Frohlich M, AlOthman B, et al. Peak Inspiratory Flow and Inhaler Prescription Strategies in a Specialized COPD Clinical Program: A Real-World Observational Study. Chest. 2024;167(3):736-45. DOI:10.1016/j.chest.2024.09.031</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>González-Montaos A, Pazos-Area L, Represas-Represas C, et al. Suboptimal Peak Inspiratory Flow in Patients Hospitalized for COPD Exacerbation: Prevalence and Predictive Factors. J Aerosol Med Pulm Drug Deliv. 2024;37(5):225-31. DOI:10.1089/jamp.2024.0002</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Trushenko NV, Lavginova BB, Chikina SY, et al. Predictors of suboptimal peak inspiratory flow in patients with acute exacerbation of chronic obstructive pulmonary disease in real clinical practice. Tuberc Respir Dis (Seoul). 2025;88(3):516-25. DOI:10.4046/trd.2024.0154</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kuek SL, Wong NX, Dalziel S, et al. Dry-powder inhaler use in primary school-aged children with asthma: a systematic review. ERJ Open Res. 2024;10(6):455-2024. DOI:10.1183/23120541.00455-2024</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Murugaiya S, Murugesan BSP. Prevalence and Factors Affecting the Optimal and Non-optimal Peak Inspiratory Flow Rate in Stable and Exacerbation Phases of Chronic Obstructive Pulmonary Disease and Bronchial Asthma in India. Cureus. 2024;16(4):e58670. DOI:10.7759/cureus.58670</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Haughney J, Lee AJ, McKnight E, et al. Peak Inspiratory Flow Measured at Different Inhaler Resistances in Patients with Asthma. J Allergy Clin Immunol Pract. 202;9(2):890-6. DOI:10.1016/j.jaip.2020.09.026</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Mohd Rhazi NA, Muneswarao J, Abdul Aziz F, et al. Can patients achieve sufficient peak inspiratory flow rate (PIFR) with Turbuhaler® during acute exacerbation of asthma? J Asthma. 2023;60(8):1608-12. DOI:10.1080/02770903.2023.2169930</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Kocks J, Wouters H, Bosnic-Anticevich S, et al. Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers. NPJ Prim Care Respir Med. 2022;32(1):18. DOI:10.1038/s41533-022-00282-y</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Azouz W, Chetcuti P, Hosker H, et al. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study. BMC Pulm Med. 2015;15:47. DOI:10.1186/s12890-015-0043-x</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Malmberg LP, Rytila P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;5:257-62. DOI:10.2147/copd.s11474</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Davidson HE, Radlowski P, Han L, et al. Clinical Characterization of Nursing Facility Residents With Chronic Obstructive Pulmonary Disease. Sr Care Pharm. 2021;36:248-57. DOI:10.4140/TCP.n.2021.248</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217-24. DOI:10.15326/jcopdf.4.3.2017.0183</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ding N, Zhang W, Wang Z, et al. Prevalence and Associated Factors of Suboptimal Daily Peak Inspiratory Flow and Technique Misuse of Dry Powder Inhalers in Outpatients with Stable Chronic Airway Diseases. Int J Chron Obstruct Pulmon Dis. 2021;16:1913-24. DOI:10.2147/COPD.S311178</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174-9. DOI:10.1089/jamp.2012.0987</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Harb HS, Laz NI, Rabea H, Abdelrahim MEA. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients. Eur J Pharm Sci. 2020;147:105298. DOI:10.1016/j.ejps.2020.105298</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305-11. DOI:10.1513/AnnalsATS.201611-903OC</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Duarte AG, Tung L, Zhang W, et al. Spirometry Measurement of Peak Inspiratory Flow Identifies Suboptimal Use of Dry Powder Inhalers in Ambulatory Patients with COPD. Chronic Obstr Pulm Dis. 2019;6(3):246-55. DOI:10.15326/jcopdf.6.3.2018.0163</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Represas-Represas C, Aballe-Santos L, Fernández-García A, et al. Evaluation of Suboptimal Peak Inspiratory Flow in Patients with Stable COPD. J Clin Med. 2020;9(12):3949. DOI:10.3390/jcm9123949</mixed-citation></ref></ref-list></back></article>
